Camber Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Camber Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,500,000	Closed	-$65.3M	–	45
2023 Q3	$65.3M	Sell	1,500,000 -300,000	-17%	-$10.7M	2.15%	19
2023 Q2	$65M	Buy	1,800,000 +400,000	+29%	+$16.5M	2.12%	17
2023 Q1	$52.1M	Hold	1,400,000	–	–	1.6%	18
2022 Q4	$63.4M	Sell	1,400,000 -600,000	-30%	-$38.8M	2.18%	17
2022 Q3	$140M	Buy	2,000,000 +1,350,000	+208%	+$99.9M	4.28%	7
2022 Q2	$43.6M	Sell	650,000 -550,000	-46%	-$35M	1.89%	19
2022 Q1	$98.7M	Buy	1,200,000 +625,000	+109%	+$63.9M	3.57%	14
2021 Q4	$84.3M	Buy	575,000 +125,000	+28%	+$19.4M	2.9%	15
2021 Q3	$79.6M	Buy	450,000 +50,000	+13%	+$8.04M	2.45%	21
2021 Q2	$64.6M	Buy	400,000 +275,000	+220%	+$44.2M	2.18%	23
2021 Q1	$21.4M	Buy	+125,000	New	+$24.7M	0.73%	30

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Camber Capital Management's MRTX Position: Q4 2023 in Review

Camber Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 1,500,000 shares — an estimated $65.3M sold.

Camber Capital Management first reported a position in MRTX in Q1 2021 and held it in 11 quarters. The position peaked at $140M in Q3 2022. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Camber Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Camber Capital Management sold 1,500,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $65.3M.
Camber Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
Camber Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $140M in Q3 2022.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Camber Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.